Table 2.
All Patients N = 124 | Healing in 6-M Group N = 61 | Non-Healing in 6-M Group N = 63 | P value | |
Aortoiliac lesion, N (%) | 9 (7.3%) | 1 (1.6%) | 8 (12.7%) | .033 |
TASC II classification | 1.000 | |||
TASC C | 2 (22.2%) | 0 (0%) | 2 (25%) | |
TASC D | 7 (77.8%) | 1 (100%) | 6 (75%) | |
CTO | 4 (3.2%) | 1 (1.6%) | 3 (4.8%) | .619 |
Vessel calcification∗ | .268 | |||
Grade 2 | 2 (22.2%) | 0 (0%) | 2 (25%) | |
Grade 3 | 3 (33.3%) | 0 (0%) | 3 (37.5%) | |
Femoropopliteal lesion, N (%) | 76 (61.3%) | 33 (54.1%) | 43 (68.3%) | .152 |
TASC II classification | .978 | |||
TASC C | 22 (28.9%) | 9 (27.3%) | 13 (30.2%) | |
TASC D | 46 (60.5%) | 20 (60.6%) | 26 (60.5%) | |
CTO | 22 (17.7%) | 13 (21.3%) | 9 (14.3%) | .430 |
Vessel calcification | .745 | |||
Grade 3 | 17 (13.7%) | 8 (13.1%) | 9 (14.3%) | |
Grade 4 | 21 (16.9%) | 9 (14.8%) | 12 (19%) | |
Infra-popliteal lesion N (%) | 120 (96.8%) | 60 (98.4%) | 60 (95.2%) | .619 |
TASC II classification | .768 | |||
TASC C | 36 (29%) | 17 (27.9%) | 19 (30.2%) | |
TASC D | 70 (56.4%) | 34 (55.7%) | 36 (57.1%) | |
CTO | 101 (81.5%) | 51 (83.6%) | 50 (79.4%) | .707 |
Vessel calcification | .299 | |||
Grade 3 | 17 (13.7%) | 7 (11.5%) | 10 (15.9%) | |
Grade 4 | 27 (21.8%) | 12 (19.7%) | 15 (23.8%) | |
Run-off vessel numbers (0/1/2/3), N | ||||
Before EVT | 31/40/37/14 | 16/16/21/8 | 15/24/16/6 | .459 |
After EVT | 1/28/63/30 | 0/9/35/17 | 1/19/28/13 | .117 |
Median run-off vessel numbers, N | ||||
Before EVT | 1.0 (0–2) | 1.0 (0–2) | 1.0 (0.5–2) | .447 |
After EVT | 2.0 (2–2.3) | 2.0 (2–3) | 2.0 (1–2) | .050 |
Occlusion of plantar arch, N (%) | 46 (38.7%) | 20 (33.3%) | 26 (44.1%) | .311 |
Procedure success | 113 (91.1%) | 57 (93.4%) | 56 (88.9%) | .565 |
Stenting | 42 (33.9%) | 15 (24.6%) | 27 (42.9%) | .050 |
Drug coating balloon | ||||
Femoropopliteal | 19 (15.3%) | 7 (11.5%) | 12 (19.0%) | .357 |
Infra-popliteal | 19 (15.3%) | 11 (18.0%) | 8 (12.7%) | .565 |
18-month clinical outcome | ||||
Target Lesion Revascularization | 18 (14.5%) | 9 (14.8%) | 9 (14.3%) | 1.000 |
All-cause mortality | 29 (23.4%) | 8 (13.1%) | 21 (33.3%) | .014 |